Results 51 to 60 of about 795,358 (192)

Generalized Pustular Psoriasis in Childhood

open access: yes, 2010
Generalized pustular psoriasis is a rare form of psoriasis consisting of a generalized eruption of sudden onset with erythema and sterile pustules.
TAKAHASHI, Maria Denise Fonseca   +4 more
core   +1 more source

Consensus‐based Guideline on tinea capitis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The consensus‐based guideline developed under the auspices of the German Dermatological Society (DDG) is intended to provide physicians with a structured framework for clinical decision‐making in the management of patients with tinea capitis and to contribute to improved diagnostic accuracy, treatment adherence, and prevention. Tinea capitis is
Peter Mayser   +19 more
wiley   +1 more source

Successful secukinumab treatment of generalized pustular psoriasis [PDF]

open access: yes
Generalized pustular psoriasis is a rare variant of psoriasis. Evidence recommending generalized pustular psoriasis treatment with secukinumab is limited.
Ma, Li-Li   +7 more
core   +1 more source

Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study

open access: yesInternational Journal of Dermatology, EarlyView.
This multicentre real‐world study illustrates the heterogeneity of systemic treatment approaches in erythrodermic psoriasis (EP) in Bavaria, Germany. Adverse events were more frequently observed with conventional therapies, whereas biologic therapies showed favorable outcomes.
Julian Kögel   +15 more
wiley   +1 more source

Methotrexate and Adalimumab Combination Efficacy in 4-year-old Child with Generalized Pustular Psoriasis: Case Study

open access: yesВопросы современной педиатрии
Background. Generalized pustular psoriasis management in children is a topical issue due to limited use and efficacy of traditional immunodepressants, absence of registered genetically engineered biologic drugs.
Nikolay N. Murashkin   +9 more
doaj   +1 more source

Evaluation of Discontinuation and Re‐Initiation of Biologic Therapies in Psoriasis: Real‐World Data

open access: yesInternational Journal of Dermatology, EarlyView.
The cumulative probability of remaining relapse‐free following biologic therapy discontinuation was 35.6%, 19%, 11.6%, and 9.1% at 6, 12, 18, and 24 months, respectively. Prolonged relapse durations were associated with a low baseline PASI score, the presence of a PASI 90 response at discontinuation, the absence of triggering factors, and the use of IL‐
Ahmet Taha Aydemir, Nihal Kundakcı
wiley   +1 more source

Spesolimab for the Treatment of Generalized Pustular Psoriasis

open access: yesDrugs, 2023
Generalized pustular psoriasis (GPP) is a rare but severe skin inflammatory disorder characterized by the eruption of widespread sterile neutrophilic pustules, often accompanied by systemic inflammation. Given its life-threatening potential, GPP requires prompt accurate diagnosis and effective treatment, but its rarity and relapsing-remitting nature ...
Diana Bernardo   +2 more
openaire   +2 more sources

Deep and disseminated dermatophytosis in immunocompromised populations—A systematic review

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Dermatophyte infections of the dermis and subcutaneous tissue (i.e. deep dermatophytosis)—associated with secondary complications including pseudomycetoma and systemic dissemination—affect vulnerable populations with primary or acquired immunodeficiencies.
Aditya K. Gupta   +5 more
wiley   +1 more source

Clinical analysis of secukinumab in the treatment of childhood generalized pustular psoriasis

open access: yesPifu-xingbing zhenliaoxue zazhi
Objective To explore the clinical efficacy and safety of secukinumab in the treatment of childhood generalized pustular psoriasis (GPP) in order to provide a new therapeutic strategy for childhood generalized pustular psoriasis.
Min YU, Zhanghong YING
doaj   +1 more source

Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Anumigilimab, a novel anti‐G‐CSF receptor antibody, was investigated in a phase 1b trial involving 39 patients with hidradenitis suppurativa or palmoplantar pustulosis. No serious safety concerns related to anumigilimab were noted, and PK and PD were dose dependent.
Johannes S. Kern   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy